Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Comments and Opinions
December 2007

British Guidelines on the Use of Biological Therapies for Psoriasis: A Note of Clarification on the Role of Etanercept

Author Affiliations

Copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2007

Arch Dermatol. 2007;143(12):1589-1603. doi:10.1001/archderm.143.12.1595-b

We are pleased that the British Association of Dermatologists guidelines on use of biological therapies in psoriasis1 have been highlighted and summarized so succinctly. We are also glad that the reviewing author, Dr Nijsten,2 found them to be “clear and informative” and that he recommends their use. However, we are concerned that his conclusion (as stated in the abstract and in the commentary) that “etanercept is the biological drug of choice in most eligible patients with stable disease with or without psoriatic arthritis” is a misrepresentation of what is stated in the guidelines. Indeed, we were very careful not to provide explicit guidance as to which of the agents covered (etanercept, infliximab, and efalizumab) should be the preferred choice given the lack of evidence available at the time.

First Page Preview View Large
First page PDF preview
First page PDF preview